Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.

Objective: To understand the long-term experience of patients receiving ide-cel chimeric antigen receptor T (CAR T) cell therapy for relapsed or refractory multiple myeloma in the pivotal phase 2 KarMMa trial.
Methods: This qualitative study analyzed semi-structured patient interviews 6-24 months after ide-cel infusion. Thematic analysis with quantitative and longitudinal analyses explored patient perceptions of ide-cel treatment experience, advantages and disadvantages, and long-term health-related quality of life impact. Patient journeys were developed from narrative analysis of perceived treatment benefits with known remission length.
Results: Interviews with 45 patients 6-24 months postinfusion were analyzed; all reported ≥ 1 ide-cel treatment advantage, most often related to efficacy (n = 42/45, 93%), few or no side effects (n = 35/45, 78%), and avoidance of other treatments (n = 34/45, 76%). Patients generally reported 6-month improvements in physical health, functioning, emotional well-being, social life, and outlook on the future; these improvements mostly remained "stable" through 18 and 24 months. The most common patient journeys comprised physical, functioning, or emotional benefit with remission < 2 years.
Conclusions: Longitudinal analysis of patient experiences showed sustained benefits and preference for ide-cel up to 24 months after treatment. Trial Registration Number and Date: NCT03361748. December 5, 2017.
Competing Interests: Declaration of Competing Interest MD has received research funding and honoraria from Amgen, Celgene, Janssen, Karyopharm, and Sanofi. PRO has served as a consultant for and received honoraria from AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen, Kite Pharma, Oncopeptides, and Sanofi; has served as a consultant for Takeda; and has served on the board of directors or advisory committee and speakers bureau for Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Oncopeptides, Regeneron, and Sanofi. NS has worked in an advisory role for Allogene Therapeutics, Amgen, CareDx, CSL Behring, GlaxoSmithKline, Indapta Therapeutics, Karyopharm, Kite Pharma, Oncopeptides, and Sanofi; has received research funding from bluebird bio, Bristol Myers Squibb/Celgene, Janssen, Nektar, Poseida, Precision Biosciences, Sutro Biopharma, and Teneobio; and is an employee and stockholder of AstraZeneca. OM, SL, MM, and HG are employees of ICON plc. JD is an employee and stockholder of ICON plc. JB, DSD, and TBC are employees and stockholders of Bristol Myers Squibb. NCM has served as a consultant for AbbVie, Adaptive, Amgen, Bristol Myers Squibb, Janssen, Legend, Novartis, Pfizer, and Takeda; has served as a consultant for, holds stock, patents and royalties in, and is a member on a board of directors or advisory committee for Oncopeptides; and is an employee of Dana Farber Cancer Institute.
(Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)